K252a inhibits the oncogenic properties of Met, the HGF receptor (Q28214703)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

K252a inhibits the oncogenic properties of Met, the HGF receptor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

Silvia Mila

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Paolo Accornero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Emma Tagliabue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

Carola Ponzetto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

language of work or name

English

0 references

publication date

1 July 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

4885-4893

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Oncogenic kinase signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Hepatocyte growth factor: a multifunctional cytokine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Anticancer drug targets: growth factors and growth factor signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Mechanism-based target identification and drug discovery in cancer research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Tyrosine kinase receptor indistinguishable from the c-met protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

A point mutation in the MET oncogene abrogates metastasis without affecting transformation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

The mutationally activated Met receptor mediates motility and metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

K-252a: a specific inhibitor of the action of nerve growth factor on PC 12 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Two mutations affecting conserved residues in the Met receptor operate via different mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Comparison of seven cell lines derived from human gastric carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

K-252a and staurosporine selectively block autophosphorylation of neurotrophin receptors and neurotrophin-mediated responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Development of inhibitors for protein tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Mechanism of met oncogene activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Frequency ofTPR-MET rearrangement in patients with gastric carcinoma and in first-degree relatives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205622

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1205622

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12118367%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

11 November 2019

1046892755

0 references

1 reference